Literature DB >> 23149832

Dyslipidemia: Phase III trial of mipomersen in heterozygous FH.

Bryony M Mearns.   

Abstract

Entities:  

Year:  2012        PMID： 23149832     DOI： 10.1038/nrcardio.2012.151

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.

Authors:  Evan A Stein; Robert Dufour; Claude Gagne; Daniel Gaudet; Cara East; Joanne M Donovan; Wai Chin; Diane L Tribble; Mary McGowan
Journal:  Circulation       Date:  2012-10-11       Impact factor: 29.690
  1 in total
  3 in total

1.  Small RNA overcomes the challenges of therapeutic targeting of microsomal triglyceride transfer protein.

Authors:  Kasey C Vickers; Kathryn J Moore
Journal:  Circ Res       Date:  2013-11-08       Impact factor: 17.367

Review 2.  MicroRNA Regulation of Atherosclerosis.

Authors:  Mark W Feinberg; Kathryn J Moore
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

Review 3.  The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials.

Authors:  Behrooz Astaneh; Nima Makhdami; Vala Astaneh; Gordon Guyatt
Journal:  J Cardiovasc Dev Dis       Date:  2021-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.